

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP03/07333

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> C07K7/06, A61K38/08, A61K38/55, A61P1/04, A61P1/14, A61P27/02, A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C07K7/06, A61K38/08, A61K38/55, A61P1/04, A61P1/14, A61P27/02, A61P43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
 Japanese Utility Model Gazette 1926-1996, Japanese Publication of Unexamined Utility Model Applications 1971-2001, Japanese Registered Utility Model Gazette 1994-2001, Japanese Gazette Containing the Utility Model 1996-2001

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS (DIALOG), WPI (DIALOG), REGISTRY (STN), CA (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/62291 A1 (FUSO PHARM IND LTD) 2001.08.30 & JP 2001-233790 A & AU 200132345 A & EP 1258251 A1	1-7
Y	WO 01/47556 A1 (FUSO PHARM IND LTD) 2001.07.05 & JP 2001-181208 A & AU 200117342 A & EP 1247532 A1	1-7
Y	Maryanoff BE et al, Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes. , Arch Biochem Biophys. , 2001, Vol. 386, No. 2, p. 195-204.	1-7
Y	Santagada V et al, Minimal structural requirements for agonist activity of PAR-2 activating peptides. , Bioorg Med Chem Lett. , 2002 Jan, Vol. 12, No. 1, p. 21-4.	1-7

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

22.07.03

Date of mailing of the international search report

05.08.03

Name and mailing address of the ISA/JP

Japan Patent Office

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

Authorized officer

Noriko Mukasa

Telephone No. +81-3-3581-1101 Ext. 3448

4B

9735

Seal

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/07333

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	D'Alessio S et al, Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides., Bioorg Med Chem., 1999, Vol.7, No.2, p.389-94.	1-7
Y	WO 97/25351 A2 (MILLENNIUM PHARM INC) 1997.07.17 &AU 9722415 A &EP 871670 A2 &US 6037324 A &JP 2000-503203 A &AU 721615 B &US 6274556 B1 &US 2002/0103111 A1	1-7
P, A	WO 02/56916 A2 (ZIMMER R H) 2002.07.25 &US 2002/0132777 A1	1-7

Claim 1-7 is not supported by the description as required by Article 6 PCT.

The reason therefor is the following:

aryl group in claim 1 contains a lot of structure, but in the description, only a few structures are disclosed.

We searched the subject matter of claim 1-7 which is supported by the description, Z  $-(CH_2)_n$  represents in the example 1-18, AA1-AA2 represents Lys-Val or Arg-Leu, and R represents -OH or -NH<sub>2</sub>.